Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001193125-23-103637
Filing Date
2023-04-17
Accepted
2023-04-17 16:09:57
Documents
2
Group Members
KEN TAKANASHISNBL U.S.A., LTD.SNBL23 MERGER SUB, INC.

Document Format Files

Seq Description Document Type Size
1 SC 13D/A d500902dsc13da.htm SC 13D/A 119237
2 EX-99.1 d500902dex991.htm EX-99.1 10141
  Complete submission text file 0001193125-23-103637.txt   131082
Mailing Address 2438 MIYANOURA-MACHI KAGOSHIMA CITY KAGOSHIMA M0 891-1394
Business Address 2438 MIYANOURA-MACHI KAGOSHIMA CITY KAGOSHIMA M0 891-1394 81-99-294-2600
Shin Nippon Biomedical Laboratories, Ltd. (Filed by) CIK: 0001657770 (see all company filings)

EIN.: 000000000 | State of Incorp.: M0 | Fiscal Year End: 1231
Type: SC 13D/A

Mailing Address 400 OYSTER POINT BOULEVARD SUITE 221 SOUTH SAN FRANCISCO CA 64080
Business Address 400 OYSTER POINT BOULEVARD SUITE 221 SOUTH SAN FRANCISCO CA 64080 415-505-0809
Satsuma Pharmaceuticals, Inc. (Subject) CIK: 0001692830 (see all company filings)

EIN.: 813039831 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-91126 | Film No.: 23824049
SIC: 2834 Pharmaceutical Preparations